Bradley RK, Anczuków O (2023) RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer 23:135–155

Article  PubMed  PubMed Central  CAS  Google Scholar 

Aubol BE, Wozniak JM, Fattet L, Gonzalez DJ, Adams JA (2021) CLK1 reorganizes the splicing factor U1-70K for early spliceosomal protein assembly. Proc Natl Acad Sci 118:e2018251118

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yoshimi A, Abdel-Wahab O (2017) Molecular pathways: Understanding and targeting mutant spliceosomal proteins. Clin Cancer Res 23:336–341

Article  PubMed  CAS  Google Scholar 

Moyano PM, Nemec V, Paruch K (2020) Cdc-like kinases (CLKs): biology, chemical probes, and therapeutic potential. Int J Mol Sci 21:7549

Article  CAS  Google Scholar 

Song M, Pang L, Zhang M, Qu Y, Laster KV, Dong Z (2023) Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases. Sig Transduc Targ Th 8:148

Google Scholar 

Corr BR, Moroney MR, Woodruff E, Watson ZL, Jordan KR, Danhorn T, Bailey C, Wolsky RJ, Bitler BG (2023) Combination CDC-like kinase Inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer. BioRxiv: Posted April 6

Riggs JR, Nagy M, Elsner J, Erdman P, Cashion D, Robinson D, Harris R, Huang D, Tehrani L, Deyanat-Yazdi G, Narla RK, Peng X, Tran T, Barnes L, Miller T, Katz J, Tang Y, Chen M, Moghaddam MF, Bahmanyar S, Pagarigan B, Delker S, LeBrun L, Chamberlain PP, Calabrese A, Canan SS, Leftheris K, Zhu D, Boylan JF (2017) The discovery of a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor for the treatment of triple negative breast cancer initiated from a phenotypic screen. J Med Chem 60:8989–9002

Article  PubMed  CAS  Google Scholar 

Zhu D, Xu S, Deyanat-Yazdi G, Peng SX, Barnes LA, Narla RK, Tran T, Mikolon D, Ning Y, Shi T, Jiang N, Raymon HK, Riggs JR, Boylan JF (2018) Synthetic lethal strategy identifies a potent and selective TTK and CLK1/2 inhibitor for treatment of triple-negative breast cancer with a compromised G1–S checkpoint. Mol Cancer Ther 1:17: 27–38

Google Scholar 

McGrath J, Trojer P (2015) Targeting histone lysine methylation in cancer. Pharmacol Ther 150:1–22

Article  PubMed  CAS  Google Scholar 

Schmidt DMZ, McCafferty DG (2007) Trans-2-phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochem 46:4408–4416

Article  CAS  Google Scholar 

Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941–953

Article  PubMed  CAS  Google Scholar 

McGrath JP, Williamson KE, Balasubramanian S, Odate S, Arora S, Hatton C, Edwards TM, Thomas O’Brien T, Magnuson S, Stokoe D, Daniels DL, Bryant BM (2016) Patrick Trojer P. Pharmacological Inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes. Cancer Res 76:1975–1988

Article  PubMed  CAS  Google Scholar 

Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG et al (2007) Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446:882–887

Article  PubMed  CAS  Google Scholar 

Maes T, Carceller E, Salas J, Ortega A, Buesaet C (2015) Advances in the development of histone lysine demethylase inhibitors. Curr Opin Pharmacol 23:52–60

Article  PubMed  CAS  Google Scholar 

Harris WJ (2012) The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21:473–487Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, Miller CJ, Donald J. Ogilvie DJ, Somervaille TCP

Article  PubMed  CAS  Google Scholar 

Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA, Marton L, Woster P, Minden MD, Dugas M, Wang JCY, Dick JE, Müller-Tidow C, Petrie K, Zelent A (2012) Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18:605–611

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maes T, Tirapu I, Mascaró C, Ortega A, Estiarte A, Castro-Palomino NV, Arjol CB, Guido Kurzet G (2013) Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia. J Clin Oncol 31:e13543

Article  Google Scholar 

Smitheman K, Cusan M, Liu Y, Butticello M, Pappalardi M, Foley J, Federowicz K, Van Aller G, Kasparec J, Tian X, Suarez D, Schneck J, Carson J, McDevitt P, Ho T, McHugh C, Miller W, Armstrong S, Hann C, Johnson N, Kruger RG, Mohammad HP (2015) Shekhar Kamat S. Inhibition of LSD1 for the treatment of cancer. Cancer Res 75:3513

Article  Google Scholar 

Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R et al (2019) Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal. https://doi.org/10.1126/scisignal.aau2922

Article  PubMed  PubMed Central  Google Scholar 

Morris J, Kunkel MW, White SL, Wishka DG, Lopez OD, Bowles L et al (2023) Targeted investigational oncology agents in the NCI-60: A phenotypic Systems-based resource. Mol Cancer Ther 22:1270–1279

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kaur G, Evans DM, Teicher BA, Coussens NP (2021) Complex tumor spheroids, a Tissue-Mimicking tumor model, for drug discovery and precision medicine. SLAS Discov 26:1298–1314

Article  PubMed  CAS  Google Scholar 

Dexheimer TS, Coussens NP, Silvers T, Wright J, Morris J, Doroshow JH, Teicher BA (2023) Multicellular complex tumor spheroid response to DNA repair inhibitors in combination with DNA-damaging drugs. Cancer Res Commun 3(8):1648–1661

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26:585–615

Article  CAS  Google Scholar 

Wang XL, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A et al (2022) Identification of MRTX1133, a noncovalent, potent, and selective KRAS inhibitor. J Med Chem 65:3123–3133

Article  PubMed  CAS  Google Scholar 

Skanland SS, Okkenhaug K, Davids MS (2024) PI3K inhibitors in hematology: when one door closes. Clin Cancer Res 30:3667–3675

Article  PubMed  PubMed Central  Google Scholar 

Song KW, Edgar KA, Hanan EJ, Hafner M, Oeh J, Merchant M, Sampath D, Nannini MA, Hong R, Phu L, Forrest WF, Stawiski E, Schmidt S, Endres N, Guan J, Wallin JJ, Cheong J, Plise EG, Lewis Phillips GD, Salphati L, Heffron TP, Alan G, Olivero AG, Malek S, Staben ST, Kirkpatrick DS, Dey A, Friedman LS (2022) RTK-dependent inducible degradation of mutant PI3Ka drives GDC-0077 (inavolisib) efficacy. Cancer Discov 12:204–219

Article  PubMed  CAS  Google Scholar 

Camilli S, Lockey R, Kolliputi N (2023) Nuclear export inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) provide a novel therapy to reduce tumor growth by induction of PANoptosis. Cell Biochem Biophys 81:421–426

Article  PubMed  CAS  Google Scholar 

Binder AF, Walker CJ, Mark TM, Baljevic M (2023) Impacting T-cell fitness in multiple myeloma: potential roles for Selinexor and XPO1 inhibitors. Front Immunol 14:1275329

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gordhandas SB, Manning-Geist B, Henson C, Iyer G, Gardner GJ, Sonoda Y, Moore KN, Aghajanian C, Chui MH, Grisham RN (2022) Preclinical activity of the oral DNA-PK inhibitor, Peposertib (M3814), combined with radiation in xenograft models of cervical cancer. Sci Rep 12:974

Article  PubMed  PubMed Central  CAS  Google Scholar 

van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz-Padilla I, Schellens JHM (2021) A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor Peposertib (formerly M3814) in patients with advanced solid tumors. Brit J Cancer 124:728–735

Article  PubMed  Google Scholar 

Samuels M, Falkenius J, Bar-Ad V, Dunst J, Triest B, Yachnin J, Rodriguez-Gutierrez A, Kuipers M, You X, Sarholz B, Locatelli G, Becker A, Troost EGC (2024) A Phase1studyof the DNA-PK inhibitor Peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors. Int J Radiat Oncol Biol Phys 118:743–756

Article